Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer

被引：0
|
作者：
Schmoll, H.
Tabernero, J.
Nowacki, M.
Maroun, J.
Price, T.
Lim, R.
Van Cutsem, E.
de Braud, F.
Haller, D.
机构：
[1] Univ Halle Wittenberg, Halle, K1Y 4K7, Germany
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Maria Sklodowska Curie Mem Canc Ctr, Inst Oncol, Warsaw 117548, Poland
[4] Ottawa Reg Canc Ctr, B-3000 Ottawa, ON, Canada
[5] Queen Elizabeth Hosp, Adelaide, SA, Australia
[6] Natl Univ Singapore Hosp, Singapore, 19104, Singapore
[7] Univ Hosp Gasthuisberg, Louvain, Belgium
[8] Ist Europeo Oncol, Milan, Italy
[9] Univ Penn, Philadelphia, PA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [1] Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, HJ
    Tabernero, J
    Nowacki, M
    Maroun, J
    Figer, A
    Price, T
    Lim, R
    van Cutsem, E
    Haller, D
    Braud, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [2] Capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    ANNALS OF ONCOLOGY, 2006, 17 : 25 - 26
  • [3] Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, H. J.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    De Braud, F.
    Haller, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [4] First efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study)
    Hailer, D.
    Tabernero, J.
    Maroun, J.
    de Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Rittweger, K.
    Schmoll, H.
    EJC SUPPLEMENTS, 2009, 7 (03): : 4 - 4
  • [5] EFFICACY FINDINGS FROM A RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL
    Haller, D.
    Cassidy, J.
    Tabernero, J.
    Maroun, J.
    De Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Schmoll, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [6] Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer.
    Twelves, C
    Wong, A
    Nowacki, M
    McKendrick, J
    van Hazel, G
    Douillard, JY
    Díaz-Rubio, E
    Cassidy, J
    Maroun, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [7] Positive efficacy results of the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
    McKendrick, Joseph
    Cassidy, James
    Van Hazel, Guy
    Twelves, Chris
    Wong, Alfred
    Nowacki, Marek
    Kroning, Hendrik
    Cervantes, Andres
    Herrmann, Richard
    Burris, Howard, III
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 74
  • [8] RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): IMPACT OF AGE ON DISEASE-FREE SURVIVAL (DFS) OR OVERALL SURVIVAL (OS)
    Haller, D.
    Cassidy, J.
    Tabernero, J.
    Maroun, J. A.
    De Braud, F.
    Price, T. J.
    van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Schmoll, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 207 - 207
  • [9] TP, TS AND DPD AS POTENTIAL PREDICTORS OF OUTCOME FOLLOWING CAPECITABINE PLUS OXALIPLATIN (XELOX) VS. BOLUS 5-FLUOROURACIL/LEUCOVORIN (5-FU/LV) AS ADJUVANT THERAPY FOR STAGE III COLON CANCER: UPDATED BIOMARKER FINDINGS FROM STUDY NO16968 (XELOXA)
    Schmoll, H.
    Tabernero, J.
    Maroun, J. A.
    De Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Hoersch, S.
    Rittweger, K.
    Haller, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 187 - 187
  • [10] Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).
    Schmoll, Hans-Joachim
    Tabernero, Josep
    Maroun, Jean Alfred
    De Braud, Filippo G.
    Price, Timothy Jay
    Van Cutsem, Eric
    Hill, Mark
    Hoersch, Silke
    Rittweger, Karen
    Haller, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345